Jump to comment:

• Corrigendum
  Mark Taylor
  Published on: 5 February 2020

• Published on: 5 February 2020

  Corrigendum

  • Mark Taylor, psychiatrist

  It is worth noting that 'RR' in the title of our article is indeed 'relative risk' but that there is no statistical inference associated with our use of this term.

  Also, I am grateful to Ross Bearman and others for pointing out some typos / errors in our paper - namely: The introduction states cannabis is a class C drug, the correct designation of class B is listed in table 1.

  Figure 2 identifies methyl...

  Show More

  It is worth noting that 'RR' in the title of our article is indeed 'relative risk' but that there is no statistical inference associated with our use of this term.

  Also, I am grateful to Ross Bearman and others for pointing out some typos / errors in our paper - namely: The introduction states cannabis is a class C drug, the correct designation of class B is listed in table 1.

  Figure 2 identifies methylphenidate as class C (should be class B)

  Figure 3 identifies benzodiazepines as class B (class C)

  Figure 3 methylphenidate as not classified (class B) All three charts identify: Ketamine as class B (class C) Buprenorphine as class B (class C) Dihydrocodeine as class C (class B) Amphetamines as class C (class B) Barbituates as class C (class B)

  Conflict of Interest:

  None declared

  Show Less

  Conflict of Interest:
  None declared.

  • Back to top